Keros Long Term Debt vs Non Current Liabilities Total Analysis

KROS Stock

USD 67.79 5.51 8.85%

Keros Therapeutics financial indicator trend analysis is infinitely more than just investigating Keros Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Keros Therapeutics is a good investment. Please check the relationship between Keros Therapeutics Long Term Debt and its Non Current Liabilities Total accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Keros Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Keros Stock please use our How to Invest in Keros Therapeutics guide.

Long Term Debt vs Non Current Liabilities Total

Long Term Debt vs Non Current Liabilities Total Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Keros Therapeutics Long Term Debt account and Non Current Liabilities Total. At this time, the significance of the direction appears to have weak relationship.

The correlation between Keros Therapeutics' Long Term Debt and Non Current Liabilities Total is 0.39. Overlapping area represents the amount of variation of Long Term Debt that can explain the historical movement of Non Current Liabilities Total in the same time period over historical financial statements of Keros Therapeutics, assuming nothing else is changed. The correlation between historical values of Keros Therapeutics' Long Term Debt and Non Current Liabilities Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt of Keros Therapeutics are associated (or correlated) with its Non Current Liabilities Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Liabilities Total has no effect on the direction of Long Term Debt i.e., Keros Therapeutics' Long Term Debt and Non Current Liabilities Total go up and down completely randomly.

Correlation Coefficient

0.39

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Long Term Debt

Long-term debt is a debt that Keros Therapeutics has held for over one year. Long-term debt appears on Keros Therapeutics balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Keros Therapeutics balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Non Current Liabilities Total

Most indicators from Keros Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Keros Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Keros Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Keros Stock please use our How to Invest in Keros Therapeutics guide.Sales General And Administrative To Revenue is likely to gain to 218.00 in 2024, whereas Tax Provision is likely to drop 0.00 in 2024.

	2023	2024 (projected)
Depreciation And Amortization	815K	857.1K
Interest Income	3.0M	3.1M

Depreciation And Amortization Interest Income

Keros Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity
Total Assets		0.64	0.85	0.6	1.0	-0.94	1.0	0.76	0.51	-0.98	-0.85	0.92	1.0	0.76	0.62	0.84	0.85	1.0	0.86	0.96	0.85	0.61	0.95	0.75	0.76	0.99
Short Long Term Debt Total	0.64		0.91	0.68	0.62	-0.56	0.58	0.98	0.83	-0.68	-0.91	0.72	0.62	0.98	0.96	0.93	0.56	0.62	0.63	0.73	0.56	0.96	0.79	0.98	0.9	0.63
Other Current Liab	0.85	0.91		0.72	0.83	-0.75	0.8	0.97	0.81	-0.89	-1.0	0.86	0.84	0.97	0.88	0.99	0.67	0.84	0.75	0.89	0.67	0.89	0.96	0.96	0.98	0.83
Total Current Liabilities	0.6	0.68	0.72		0.56	-0.35	0.54	0.73	0.86	-0.54	-0.73	0.59	0.57	0.74	0.78	0.75	0.28	0.57	0.29	0.7	0.28	0.78	0.6	0.73	0.71	0.54
Total Stockholder Equity	1.0	0.62	0.83	0.56		-0.95	1.0	0.73	0.47	-0.98	-0.83	0.91	1.0	0.74	0.59	0.82	0.86	1.0	0.87	0.96	0.86	0.58	0.95	0.73	0.75	0.99
Other Liab	-0.94	-0.56	-0.75	-0.35	-0.95		-0.95	-0.65	-0.27	0.93	0.76	-0.93	-0.95	-0.65	-0.46	-0.72	-0.96	-0.95	-0.96	-0.9	-0.96	-0.45	-0.89	-0.64	-0.66	-0.94
Net Tangible Assets	1.0	0.58	0.8	0.54	1.0	-0.95		0.7	0.43	-0.97	-0.79	0.9	1.0	0.7	0.55	0.79	0.86	1.0	0.86	0.95	0.86	0.54	0.93	0.69	0.7	0.98
Property Plant And Equipment Net	0.76	0.98	0.97	0.73	0.73	-0.65	0.7		0.86	-0.79	-0.96	0.78	0.74	1.0	0.96	0.98	0.6	0.74	0.67	0.82	0.6	0.97	0.88	1.0	0.94	0.73
Current Deferred Revenue	0.51	0.83	0.81	0.86	0.47	-0.27	0.43	0.86		-0.55	-0.8	0.47	0.49	0.87	0.94	0.85	0.16	0.49	0.24	0.6	0.16	0.94	0.65	0.87	0.81	0.45
Net Debt	-0.98	-0.68	-0.89	-0.54	-0.98	0.93	-0.97	-0.79	-0.55		0.88	-0.89	-0.98	-0.8	-0.65	-0.88	-0.82	-0.98	-0.86	-0.93	-0.82	-0.64	-0.98	-0.78	-0.82	-0.97
Retained Earnings	-0.85	-0.91	-1.0	-0.73	-0.83	0.76	-0.79	-0.96	-0.8	0.88		-0.88	-0.83	-0.96	-0.87	-0.98	-0.7	-0.83	-0.77	-0.9	-0.7	-0.88	-0.95	-0.96	-0.98	-0.83
Accounts Payable	0.92	0.72	0.86	0.59	0.91	-0.93	0.9	0.78	0.47	-0.89	-0.88		0.9	0.79	0.62	0.83	0.92	0.9	0.93	0.96	0.92	0.62	0.91	0.77	0.82	0.9
Cash	1.0	0.62	0.84	0.57	1.0	-0.95	1.0	0.74	0.49	-0.98	-0.83	0.9		0.75	0.6	0.83	0.85	1.0	0.86	0.95	0.85	0.59	0.95	0.73	0.75	0.99
Non Current Assets Total	0.76	0.98	0.97	0.74	0.74	-0.65	0.7	1.0	0.87	-0.8	-0.96	0.79	0.75		0.96	0.99	0.6	0.75	0.67	0.83	0.6	0.96	0.89	1.0	0.94	0.73
Non Currrent Assets Other	0.62	0.96	0.88	0.78	0.59	-0.46	0.55	0.96	0.94	-0.65	-0.87	0.62	0.6	0.96		0.93	0.39	0.6	0.47	0.7	0.39	1.0	0.76	0.97	0.86	0.59
Other Assets	0.84	0.93	0.99	0.75	0.82	-0.72	0.79	0.98	0.85	-0.88	-0.98	0.83	0.83	0.99	0.93		0.64	0.83	0.71	0.89	0.64	0.92	0.94	0.98	0.95	0.81
Long Term Debt	0.85	0.56	0.67	0.28	0.86	-0.96	0.86	0.6	0.16	-0.82	-0.7	0.92	0.85	0.6	0.39	0.64		0.85	0.99	0.83	1.0	0.39	0.79	0.59	0.61	0.87
Cash And Short Term Investments	1.0	0.62	0.84	0.57	1.0	-0.95	1.0	0.74	0.49	-0.98	-0.83	0.9	1.0	0.75	0.6	0.83	0.85		0.86	0.95	0.85	0.59	0.95	0.73	0.75	0.99
Common Stock Total Equity	0.86	0.63	0.75	0.29	0.87	-0.96	0.86	0.67	0.24	-0.86	-0.77	0.93	0.86	0.67	0.47	0.71	0.99	0.86		0.84	0.99	0.47	0.85	0.67	0.7	0.88
Common Stock Shares Outstanding	0.96	0.73	0.89	0.7	0.96	-0.9	0.95	0.82	0.6	-0.93	-0.9	0.96	0.95	0.83	0.7	0.89	0.83	0.95	0.84		0.83	0.69	0.95	0.81	0.81	0.92
Long Term Debt Total	0.85	0.56	0.67	0.28	0.86	-0.96	0.86	0.6	0.16	-0.82	-0.7	0.92	0.85	0.6	0.39	0.64	1.0	0.85	0.99	0.83		0.39	0.79	0.59	0.61	0.87
Non Current Liabilities Total	0.61	0.96	0.89	0.78	0.58	-0.45	0.54	0.97	0.94	-0.64	-0.88	0.62	0.59	0.96	1.0	0.92	0.39	0.59	0.47	0.69	0.39		0.75	0.97	0.87	0.58
Capital Surpluse	0.95	0.79	0.96	0.6	0.95	-0.89	0.93	0.88	0.65	-0.98	-0.95	0.91	0.95	0.89	0.76	0.94	0.79	0.95	0.85	0.95	0.79	0.75		0.87	0.89	0.93
Capital Lease Obligations	0.75	0.98	0.96	0.73	0.73	-0.64	0.69	1.0	0.87	-0.78	-0.96	0.77	0.73	1.0	0.97	0.98	0.59	0.73	0.67	0.81	0.59	0.97	0.87		0.93	0.73
Other Current Assets	0.76	0.9	0.98	0.71	0.75	-0.66	0.7	0.94	0.81	-0.82	-0.98	0.82	0.75	0.94	0.86	0.95	0.61	0.75	0.7	0.81	0.61	0.87	0.89	0.93		0.75
Other Stockholder Equity	0.99	0.63	0.83	0.54	0.99	-0.94	0.98	0.73	0.45	-0.97	-0.83	0.9	0.99	0.73	0.59	0.81	0.87	0.99	0.88	0.92	0.87	0.58	0.93	0.73	0.75

Click cells to compare fundamentals

Keros Therapeutics Account Relationship Matchups

Keros Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	11.0M	269.4M	255.3M	306.8M	370.0M	227.3M
Short Long Term Debt Total	5.3M	899K	1.1M	13.3M	14.4M	15.2M
Other Current Liab	107K	4.0M	6.4M	12.2M	17.9M	18.8M
Total Current Liabilities	4.5M	7.2M	11.8M	16.5M	24.4M	13.9M
Total Stockholder Equity	5.5M	261.7M	243.2M	277.4M	332.2M	207.7M
Net Tangible Assets	(19.4M)	261.7M	243.2M	277.4M	319.0M	166.3M
Property Plant And Equipment Net	1.9M	1.6M	2.4M	17.6M	19.5M	20.4M
Current Deferred Revenue	1.9M	4.4M	7.1M	17.3M	19.8M	20.8M
Net Debt	(5.7M)	(265.0M)	(228.9M)	(265.8M)	(316.7M)	(300.9M)
Retained Earnings	(19.7M)	(65.0M)	(123.8M)	(228.4M)	(381.4M)	(362.4M)
Accounts Payable	2.1M	2.1M	3.6M	3.3M	5.5M	3.1M
Cash	7.0M	265.9M	230.0M	279.0M	331.1M	208.3M
Non Current Assets Total	2.0M	1.7M	3.8M	21.0M	22.7M	23.9M
Other Assets	115K	993K	1.4M	3.4M	4.0M	4.2M
Cash And Short Term Investments	7.0M	265.9M	230.0M	279.0M	331.1M	208.3M
Liabilities And Stockholders Equity	11.0M	269.4M	255.3M	306.8M	370.0M	227.3M
Non Current Liabilities Total	1.0M	538K	231K	12.8M	13.4M	14.1M
Capital Surpluse	203K	326.7M	366.9M	505.9M	581.7M	610.8M
Capital Lease Obligations	1.3M	899K	1.1M	13.3M	14.4M	15.2M
Other Current Assets	226K	1.6M	3.2M	5.9M	15.1M	15.8M
Other Stockholder Equity	25.1M	596.2M	366.9M	505.9M	713.6M	404.8M
Total Liab	5.5M	7.7M	12.1M	29.4M	37.8M	19.6M
Net Invested Capital	5.5M	261.7M	243.2M	277.4M	332.2M	204.0M
Property Plant And Equipment Gross	1.9M	1.6M	2.4M	17.6M	21.2M	22.2M
Total Current Assets	8.9M	267.7M	251.4M	285.8M	347.3M	217.6M
Non Current Liabilities Other	119K	62K	231K	12.8M	14.7M	15.5M
Net Working Capital	4.4M	260.5M	239.6M	269.2M	322.9M	203.6M
Short Term Debt	376K	846K	1.7M	910K	1.0M	921.6K
Property Plant Equipment	1.9M	1.6M	1.3M	2.0M	2.3M	1.8M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Keros Stock Analysis

When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC